Express Pharma
Home  »  Latest Updates  »  NATCO receives DCG(I) approval for hepatitis C drug

NATCO receives DCG(I) approval for hepatitis C drug

5

The company plans to launch this combination drug immediately, under its brand name Hepcinat LP

Natco Pharma has received approval for the generic version of ledipasvir+sofosbuvir combination from Drugs Controller General (India). Natco plans to launch this combination drug immediately, under its brand name Hepcinat LP, and through its strategic partners in India.

Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences, under its brand Harvoni. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. This single-tablet regimen is the first of its kind to offer significantly higher cure rates in Genotype-1 CHC infection compared to conventional therapies.

NATCO had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of Harvoni, in 100 other developing countries in addition to India.

Comments are closed.